论文部分内容阅读
米非司酮配伍前列腺素用于药物流产(简称药流)具有安全可靠、简便易行等优点,但流产后出现的出血多、出血时间长影响了它的进一步推广。近来有报道米非司酮对人体血液纤溶系统有一定影响,但对人组织型纤溶酶原激活因子(t-PA)及其抑制因子(PAI)的研究较少报道。本文通过测定早孕妇女口服米非司酮前后血浆t-PA、PAI的活性,探讨药流术后出血原因,为临床诊治提供依据。
Mifepristone with prostaglandin for medical abortion (referred to as medical abortion) is safe, reliable, simple and easy, but the bleeding after abortion and more bleeding for a long time affected its further promotion. Recently, it has been reported that mifepristone has some influence on the blood fibrinolytic system in human body. However, the study of human tissue plasminogen activator (t-PA) and its inhibitory factor (PAI) has not been reported yet. In this paper, the determination of t-PA and PAI in plasma of early pregnant women before and after oral administration of mifepristone to explore the causes of bleeding after medical abortion, to provide a basis for clinical diagnosis and treatment.